Blog entry by mohammad katout
Dr Alaa Sabry blogged:
ERA/EDTA Friday activity Update : Polycystic Kidney Disease: clinical studies:
1-Vaptans in ADPKD (Professor Vicente Torres):
Discussed the pathogenesis of PKD and the contribution of increased CAM in the cyst growth and diseases progression with plenty of evidences and its role in upregualtion of PKD activity and possible role V2R antagonists in the treatment –The design of TEMPO study ( Tolvaptan Efficacy and Safety in Management of CKD and Outcomes ) the group received Tolvaptan showed decrease in TKV – total kidney volume- was well tolerated.
Data analysis for the result of Tempo 3-4 study is going and result is expected late 2012.